NCT05548296 2026-01-22
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Acrivon Therapeutics
Phase 2 Recruiting
Acrivon Therapeutics
Merck Sharp & Dohme LLC
Yonsei University
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center